Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical study is evaluating SV001 for safety, tolerability, pharmacokinetics and immunogenicity in people with idiopathic pulmonary fibrosis and is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• SV001

Snippet

Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. | Conditions: Idiopathic Pulmonary Fibrosis(IPF) | Phase 2 | Status: RECRUITING